Results 81 to 90 of about 3,737,366 (186)

Efficacy of Conversion Surgery for Initially Unresectable Biliary Tract Cancer That Has Responded to Down-Staging Chemotherapy

Background: Due to the limited efficacy of chemotherapy alone in the treatment of unresectable biliary tract cancer, we performed conversion surgery in patients with unresectable biliary tract cancer who responded to down-staging chemotherapy.
Takafumi Kumamoto, Shin Maeda, Yuki Homma, Shoji Yamanaka, Yu Sawada, Kazuhisa Takeda, Yasuhiro Yabushita, Takashi Murakami, Itaru Endo, Ryusei Matsuyama, Kentaro Miyake   +10 more
core   +1 more source

Immunotherapy in biliary tract cancer: reshaping the tumour microenvironment and advancing precision combination strategies

Frontiers in Immunology
Biliary tract cancer, which includes intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and gallbladder cancer, presents a significant clinical challenge because of its aggressive nature and limited therapeutic options.
Jingnan Xue, Longhao Zhang, Kai Zhang, Kai Zhou, Haitao Zhao   +4 more
doaj   +1 more source

Burden of mortality from hepatocellular carcinoma and biliary tract cancers by race and ethnicity and sex in US, 2018–2023 [PDF]

Clinical and Molecular Hepatology
Background/Aims The trends in mortality of hepatocellular carcinoma (HCC) and biliary tract cancers stratified by sex and race/ethnicity in the US continue to evolve.
Donghee Kim, Richie Manikat, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed   +4 more
doaj   +1 more source

Incidence and Overall Survival of Biliary Tract Cancers in South Korea from 2006 to 2015: Using the National Health Information Database

Gut and Liver, 2019
Background/Aims There have been no nationwide studies to investigate the trends in incidence and 5-year survival rates of intra- and extrahepatic bile duct cancers and gall-bladder cancer.
Byung-Woo Kim, Chang-Mo Oh, Hwa Young Choi, Joong-Won Park, Hyunsoon Cho, Moran Ki   +5 more
doaj   +1 more source

Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug Targets

, 2019
Genomic Profiling of Biliary Tract Cancer Cell Lines Reveals Molecular Subtypes and Actionable Drug ...
JM Mariadason (14446839), IY Luk (14446827), T Limpaiboon (13527325), M Nikfarjam (13527331), NC Tebbutt (11078790), T Muramatsu (13527337), CM Reehorst (14446824), Y Saito (7694240), DK Lau (15830402), GF Iatropoulos (15830411), LJ Jenkins (14652791), AJ Weickhardt (15830414), Amardeep Dhillon (13066923), D Mouradov (13323684), YH Yeung (15830408), W Wasenang (13527319), CM Scott (15830405), F Chionh (13404273), D Croagh (13350816), OM Sieber (14430399), DS Williams (14446830)   +20 more
core  

Half-maximal inhibitory concentration (IC₅₀) of gemcitabine in four biliary tract cancer (BTC) cell lines.

, 2018
Half-maximal inhibitory concentration (IC50) of gemcitabine in four biliary tract cancer (BTC) cell lines.
Jin Won Kim (224828), Ji Kon Ryu (481706), Jin-Hyeok Hwang (249030), Haeryoung Kim (3692143), Woo Hyun Paik (481705), Jong-chan Lee (6091127), Jaihwan Kim (481708), Sang Hyub Lee (5047862), Yong-Tae Kim (249037)   +8 more
core   +1 more source

Immunohistochemical Staining of SFRP1 and β-catenin expression in human biliary tract cancer versus normal bile duct tissues.

, 2014
Immunohistochemical Staining of SFRP1 and β-catenin expression in human biliary tract cancer versus normal bile duct tissues.
Yunfu Cui (530096), Zhanliang Hu (530094), Peng Huang (105814), Chunlong Li (530091), Sheng Tai (530095), Ming Wan (530090), Zhidong Wang (530092), Pengcheng Kang (530089), Xiangyu Zhong (530093)   +8 more
core   +1 more source

Experts’ position on durvalumab treatment for cholangiocarcinoma patients

Oncology in Clinical Practice
In the Polish population, biliary tract cancers account for about 1% of the incidence and 2.5% of deaths due to all cancers, with 85% of all cases diagnosed in patients over the age of 60.
Michał F. Kamiński, Nastazja Pilonis, Leszek Kraj, Maciej Kawecki, Tomasz Kubiatowski   +4 more
doaj   +1 more source

Causal relationship between immune cell phenotypes and risk of biliary tract cancer: evidence from Mendelian randomization analysis

Frontiers in Immunology
BackgroundBiliary tract cancer stands as a prevalent illness, posing significant risks to human health, where immune cells are pivotal in both its development and recovery processes.
YaLan Hu, Kui Wang, Kui Wang, Yuhua Chen, Yongli Jin, Qiang Guo, Hui Tang   +6 more
doaj   +1 more source

Aberrant promoter hypermethylation in biliary tract carcinoma

, 2006
論文(Article)Biliary tract carcinoma is a relatively rare tumor with a poor survival rate. The molecular biological mechanisms underlying the development of biliary tract carcinomas are not well understood.
Koga, Y, Kitajima, Y, Kohya, N, Miyazaki, K, 84078, 84077, 84076, 84075   +7 more
core